Replies to post #514143 on NorthWest Biotherapeutics Inc (NWBO)

[X Master]

The primary endpoint was changed PRIOR TO UNBLINDING. This is acceptable to the FDA. Your post is misleading.

[hoffmann6383]

Sooo many bullshit narratives just in that first paragraph alone. First, OS is the gold standard. PFS is now irrelevant in this field. I personally base my dd on updated scientific understanding. Next, as far as the post hoc, complete bullshit. See red text:

[SkyLimit2022]

Your postings are very repetitive, but I love to read them. Your postings are very repetitive, but I love to read them.

This particular posting reminds me of a few fun facts:

Dr. Linda Liau is a world-renowned neuro-oncologist, surgeon, and educator at UCLA where she is also the chair of the department of neurosurgery. As her paper on DCVax moves through the independent peer review process, it is interesting to note that she was once the editor-in-chief of a neuro-oncology medical journal.

https://www.uclahealth.org/providers/linda-liau

Across the pond from Dr. Liau, Dr. Ashkan was the chief investigator of the DCVax trial for patients in Europe. At King’s College in London, Ashkan is the lead clinician for neuro-oncology and the chair of the King’s Neurosciences Clinical Trial Unit. He is a world-renowned cancer trial expert. A few years ago, Professor Ashkan was named the UK Clinician of the Year by The Brain Tumour Charity. Additionally, Ashkan serves as an advisor to the U.K. government.

https://www.kcl.ac.uk/people/keyoumars-ashkan

Thank you for reminding us of these relevant facts!